American Council on Science and Health – April 13
There are other "dark horse" candidates who are also well regarded epidemiologists and could get the nod: Dr. Anna Giuliano, Founding Director of the Center for Infection Research in Cancer at Moffitt Cancer Center & Research Institute in Tampa; Dr. David Richardson, Director, Program in Occupational Epidemiology at UNC Chapel Hill; Dr. David Whiteman, Deputy Director at QIMR Berghofer Medical Research Institute in Brisbane.
SmallCaps.com – April 11
An initial cohort of 16 patients reached dose-escalation during the phase 1b stage of the trial conducted in the US at Albert Einstein College of Medicine in New York (Montefiore Cancer Center), under the guidance of well-regarded breast cancer specialist Prof Joseph Sparano, and at H. Lee Moffitt Cancer Center.
The ASCO Post – April 10
In a wide-ranging interview with The ASCO Post, Frederick L. Locke, MD, Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida, and co-lead investigator of the ZUMA-1 trial, discussed the significance of the trial results for patients with aggressive NHL, the possible reasons for variation in response to therapy, and how to evaluate the cost of CAR T-cell treatment vs its value.
OncLive – April 10
Jonathan R. Strosberg, MD: I think there are still a lot of unmet needs. One is simply learning how to best tailor the current treatments that we have—learning how to sequence them and, maybe even more importantly, learning how to predict which patients will respond to which treatment.
The ASCO Post – April 10
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, Tampa, directed attendees during a Poster Walk.
Financial News Feed – April 10
The Phase 1b trial was undertaken with the leadership of renowned breast cancer specialist Professor Joseph Sparano, MD, and the H. Lee Moffitt Cancer Center in Tampa (Moffitt) at the Montefiore Medical Center, Albert Einstein College of Medicine in New York.
Finance – April 10
The phase 1b trial was undertaken with the leadership of breast cancer specialist Professor Joseph Sparano, MD, and the H. Lee Moffitt Cancer Center in Tampa at the Montefiore Medical Center, Albert Einstein College of Medicine in New York.
OncLive – April 9
Bijal D. Shah, MD: I think what we’re all saying is that we’re excited that we get to personalize therapy for our patients based on their biology, based on their response. We get to personalize it with nonchemotherapeutic options that have a potential to very meaningfully impact their survival. So, without a question, that’s what I’m excited about.
Fox 13 – April 9
At Moffitt Cancer Center, Oksana Shavaryn-Sharkey helps save lives. When she's not working her day job, she's at the track, racing for them.
Medscape – April 9
"It can be very difficult for patients to wait when they know they have cancer. That is definitely one of the big barriers when you're considering not actively treating any kind of cancer," said Brandon Manley, MD, Moffitt Cancer Center, Tampa, Florida, who was not involved in the study.
Tampa Bay Business Journal – April 9
Then, in 2014, he started the annual Richard’s Father’s Day Walk & Jog fundraiser. Last year, the Gonzmart Family Foundation donated $100,000 to Moffitt Cancer Center as a result of this event, with the money earmarked for the Advanced Prostate Cancer Collaboration there.
Public Now – April 9
It was no surprise to Spooner that the Tampa Bay Times once again named Moffitt a Top Workplace for 2018. This is the eighth time Moffitt has been featured on the list.
Medical Health News – April 8
Recipients of this year's proceeds from the 5K and walk/run will be the Richard David Kann Melanoma Foundation, Melanoma Research at The Moffitt Cancer Center, The Dermatology Clinic at The Caridad Center and The League of Ribbons at Lynn Cancer Institute. Also posted to Medical Health News.
SELF Magazine – April 6
“Any growth, whether cancerous or benign could present as a lump,” Frederick Locke, M.D., a medical oncologist and program co-leader of immunology for Moffitt Cancer Center, tells SELF. So you want to keep an eye on it.
OncLive – April 6
Jonathan R. Strosberg, MD: There are several promising new therapies on the horizon. They haven’t completed testing yet, so we don’t know how active they’ll be. Some of them exploit the somatostatin receptor, so there are new somatostatin analogs conjugated to cytotoxic drugs that deliver cytotoxic therapy to neuroendocrine tumors.
OncLive –April 6
In an interview during the 2018 with OncLive® State of the Science SummitTM on Breast Cancer, Han, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discussed emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.